Ligritinib vs Mecbotamab vedotin (CAB-AXL-ADC)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: AXL · full Non-Small Cell Lung Cancer pipeline
Ligritinib
Developed by Arcus Biosciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Mecbotamab vedotin (CAB-AXL-ADC)
Developed by BioAtla, Inc.
NCT04681131 · Phase 2 · completed
The study was nonrandomized and open-label, with two experimental treatment groups and no placebo or active comparator. Its primary efficacy endpoint was objective tumor response assessed by RECIST. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Confirmed Objective Response Rate (ORR) per RECIST v1.1 (Up to 24 months); Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5 (Up to 24 months): BA3011 (CAB-AXL-ADC/mecbotamab vedotin) monotherapy in PD-1/L1-treatment-failure NSCLC patients evaluable at 12 weeks: ORR 27.8%, disease control rate 55.6%, median duration of response 4.8 months (range 2.3-12.1+ months) (not_applicable)
Result source: NCT04681131
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ligritinib | Mecbotamab vedotin (CAB-AXL-ADC) |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | 27.8%abNCT04681131 |
| Duration of response, median | —Not reported | 4.8abNCT04681131 |
PFS, median
- Ligritinib
- —Not reported
- Mecbotamab vedotin (CAB-AXL-ADC)
- —Not reported
OS, median
- Ligritinib
- —Not reported
- Mecbotamab vedotin (CAB-AXL-ADC)
- —Not reported
ORR
- Ligritinib
- —Not reported
- Mecbotamab vedotin (CAB-AXL-ADC)
- 27.8%abNCT04681131
Duration of response, median
- Ligritinib
- —Not reported
- Mecbotamab vedotin (CAB-AXL-ADC)
- 4.8abNCT04681131
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ligritinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Mecbotamab vedotin (CAB-AXL-ADC)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ligritinib's landscape · Mecbotamab vedotin (CAB-AXL-ADC)'s landscape